Results for: Quiz 1z0-076 - Oracle Database 19c: Data Guard Administration Marvelous Reliable Exam Sample 🔡 Download ▷ 1z0-076 ◁ for free by simply searching on “ www.pdfvce.com ” 😙1z0-076 Valid Test Tips

Delays in diagnosis, treatment: MS patient survey

July 19, 2017

…to employment status, 38.6% of respondents reported they were employed full- or part-time; 27.4% were unemployed; 32.2% were retired; and 1.9% were students. Regarding the use of disease-modifying therapies (DMT), 72.1% were currently on treatment, 19.9% had stopped therapy, and 8.3% had never started treatment. Persons who were unemployed (n=103) or retired (n=120) were more likely to have stopped a treatment (26.9% and 24.7%, respectively). The…

MS Sequencing: Part 5 – Strategies for optimizing response

June 29, 2017

…d relapse rate (ARR) was significantly lower with fingolimod vs. interferon-β-1a IM in TRANSFORMS (0.16 vs. 0.33); with ocrelizumab vs. interferon-β-1a SC in OPERA I/II ((0.16 vs. 0.29); and with alemtuzumab vs. interferon-β-1a SC in CARE-MS I (0.18 vs. 0.39) (Cohen et al. N Engl J Med 2010;362:402-415. Hauser et al. N Engl J Med 2017;376:221-234. Cohen et al. Lancet 2012;380:1819-1828). Improvements were also seen when interferon-treated subjects…

Progressive MS studies

May 19, 2017

…e was unchanged from baseline. Siponimod: This novel agent is a sphingosine-1-phosphate (S1P) receptor modulator selective for S1P1 and S1P5 receptors. The clinical development program includes EXPAND, a phase III trial in SPMS (Kappos et al. AAN 2017; CT.002). Subjects received placebo or siponimod 2 mg/day after a 6-day dose titration. The proportion of patients with 24-week confirmed disability progression was 19.9% with siponimod vs. 25.5% wit…

Disease-modifying therapies in MS: long-term data

May 10, 2017

…ract S24.005). ARR remained low (0.15), and 84-89% of patients were relapse-free in each of Years 3-6. Over the 6-year observation period, 77% of patients had no 6-month confirmed disability worsening; 34% experienced confirmed disability improvement. The mean change from baseline in EDSS score was +0.04 points. The proportion of patients free of new Gd-enhancing T1 and new/enlarging T2 lesions was 87% and 67%, respectively, in Year 6 (Arnold et a…

AAN 2017 DAILY REPORT

April 27, 2017

…) (Mckechnie et al. AAN 2017; abstract P2.345). Three sub-fractions (VLDL-2-free cholesterol, VLDL-1 cholesterol and total triglycerides) were correlated with EDSS score independently of age or sex, and could discriminate RRMS from healthy controls with high specificity (1.0) and sensitivity (0.75). DMT discontinuation: Most older patients with RRMS who discontinue their DMT have low rates of clinical or radiological disease activity (Hua et al. A…